Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 2448.

https://doi.org/10.1182/blood-2021-154490

Published: 2021

Journal Articles

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Jeffrey A. Zonder, Dahlia Sano, Michael Maris, Alexander Lesokhin, Gottfried von Keudell, Catherine Lai, Rod Ramchandren, Tina Catalano, Gloria H. Y. Lin, Bob Uger, Penka S. Petrova, Naomi Molloy, Ingmar Bruns, Swaminathan P Iyer

Blood (2021) 138 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2021-153683

Published: 2021

Journal Articles

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, MD, Radhakrishnan Ramchandren, MD, Michael Maris, MD, Alexander M. Lesokhin, MD, Gottfried R. von Keudell, MD PhD, Bruce D. Cheson, MD, Jeff Zonder, MD, Erlene K. Seymour, MD, Tina Catalano, MSc, Gloria H. Y. Lin, PhD, Bob Uger, PhD, Penka S. Petrova, PhD, Kathleen Roberge, ANP, MSc, Yaping Shou, MDPhD, Swami P. Iyer, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136607

Published: 2020

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-136198

Published: 2020

Journal Articles

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew H. Taylor, MD, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Theresa Thompson, Robert A. Uger, PhD, Yaping Shou, MD PhD, Oleg E. Akilov, MD

Blood (2018) 132 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2018-99-116915

Published: 2018

Journal Articles

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Stephen M Ansell, MD PhD, Ian W. Flinn, MD PhD, Michael B. Maris, MD, Owen A. O'Connor, MD, PhD, Alexander Lesokhin, MD, Anjali S. Advani, MD, Mark D. Minden, MD PhD, Mary Beth M. Percival, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Meghan Irwin, BSc, EMBA, Penka S. Petrova, PhD, Robert A. Uger, PhD, Eric L Sievers, MD, Robert W. Chen, MD

Blood (2017) 130 (Supplement 1): 4116.

https://doi.org/10.1182/blood.V130.Suppl_1.4116.4116

Published: 2017

Journal Articles

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew Taylor, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Meghan Irwin, BSc, EMBA, Eric L Sievers, MD, Oleg E. Akilov, MD

Blood (2017) 130 (Supplement 1): 4076.

https://doi.org/10.1182/blood.V130.Suppl_1.4076.4076

Published: 2017

NARROW

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Email alerts

ASH Publications

American Society of Hematology

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only